skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Mycophenolic acid formulations in adult renal transplantation – update on efficacy and tolerability

Review

(2247) Views  (753) Full article downloads

Authors: Déla Golshayan, M Pascual, Bruno Vogt

Published Date April 2009 Volume 2009:5 Pages 341 - 351
DOI: http://dx.doi.org/10.2147/TCRM.S3496

Déla Golshayan1,2, M Pascual2, Bruno Vogt1

1Service of Nephrology and Hypertension, 2Transplantation Centre and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, 1011 Lausanne, Switzerland

Abstract: The description more than 30 years ago of the role of de novo purine synthesis in T and B lymphocytes clonal proliferation opened the possibility for selective immunosuppression by targeting specific enzymatic pathways. Mycophenolic acid (MPA) blocks the key enzyme inosine monophosphate dehydrogenase and the production of guanosine nucleotides required for DNA synthesis. Two MPA formulations are currently used in clinical transplantation as part of the maintenance immunosuppressive regimen. Mycophenolate mofetil (MMF) was the first MPA agent to be approved for the prevention of acute rejection following renal transplantation, in combination with cyclosporine and steroids. Enteric-coated mycophenolate sodium (EC-MPS) is an alternative MPA formulation available in clinical transplantation. In this review, we will discuss the clinical trials that have evaluated the efficacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy. We will also discuss MPA pharmacokinetics and the rationale for therapeutic drug monitoring in optimizing the balance between efficacy and safety in individual patients.

Keywords: kidney transplantation, immunosuppression, mycophenolic acid, mycophenolate mofetil, enteric-coated mycophenolate sodium, acute rejection, chronic allograft nephropathy








Readers of this article also read:

Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Mycophenolic acid agents: is enteric coating the answer?
New onset diabetes after transplantation (NODAT): an overview
Perception of risk and benefit in patient-centered communication and care
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum